Zebularine

Dnmt inhibitor



BML-GR344-0010	10 mg	103.00 USD

Zebularine is a novel DNA methylation inhibitor which acts by forming a covalent complex with DNMT. It displays antiangiogenic activity and markedly inhibits vessel formation in different tumor models. It reactivates silenced E-cadherin and potentiates the effects of other epigenetic therapeutics such as vorinistat.

Product Specification

Alternative Name:	1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one, 2-Pyrimidone-1-β-D-riboside

Purity Detail:	TLC: 30% Methanol/methylene chloride + 1% H₂O, Rf = 0.3

Formula:	C₉H₁₂N₂O₅

MW:	228.2

Purity:	≥98% (TLC)

Appearance:	Off-white solid.

CAS:	3690-10-6

Solubility:	Soluble in water (>25 mg/ml) or DMSO (>25 mg/ml).

Application:	In vitro or cell based studies.

Short Term Storage:	-20°C

Long Term Storage:	-20°C

Use/Stability:	Store solutions at -20°C for up to 3 months.

Please mouse over

Product Literature References

Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells: M. Billam, et al.; Breast Cancer Res. Treat. Inst. 120, 581 (2010), Abstract;

Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells: S.P. Rao, et al.; Mol. Cancer 6, 3 (2007), Abstract;

Angiostatic activity of DNA methyltransferase inhibitors: D.M.E.I. Hellebrekers, et al.; Mol. Cancer Ther. 5, 467 (2006), Abstract;

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases: L. Zhou, et al.; J. Mol. Biol. 321, 591 (2002), Abstract;